Pharmaceutical Technology

SEPTEMBER 22, 2023

JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.

Development 246

Development Research Production 246

Bio Pharma Dive

SEPTEMBER 22, 2023

Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

Medicine 173

Medicine 173

Pharmaceutical Technology

SEPTEMBER 22, 2023

A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.

Gene Therapy 246

Gene Therapy Gene Trials 246

Bio Pharma Dive

SEPTEMBER 22, 2023

The drug, which is already cleared as a neoadjuvant lung cancer treatment, could further compete with Merck’s Keytruda if it gains approval in the adjuvant setting for patients with the non-small cell form of the disease.

Trials 164

Trials Drugs 164

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

147

147

Bio Pharma Dive

SEPTEMBER 22, 2023

Compared to chemotherapy, a combination of Seagen’s Padcev and Merck’s Keytruda was significantly better at keeping bladder cancer patients alive longer and their disease from progressing.

Trials 164

Trials Drugs 164

Fierce Pharma

SEPTEMBER 22, 2023

Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. | Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the duo has missed the mark in yet another set of clinical trials—this time in non-small cell lung cancer.

Clinical Trials 138

Clinical Trials Clinical Trials Trials 138

Pharmaceutical Technology

SEPTEMBER 22, 2023

The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.

147

147

Antidote

SEPTEMBER 22, 2023

Connecting patients with clinical research opportunities is our mission here at Antidote, but often, we find that misconceptions can serve as barriers to achieving this goal. It’s important to carefully weigh the pros and cons of participating in a clinical trial but to do this effectively, it’s critical to have accurate information.

Clinical Trials 122

Clinical Trials Clinical Trials Trials Clinical Research 122

Pharmaceutical Technology

SEPTEMBER 22, 2023

Debiopharm and SunRock Biopharma have signed an agreement to advance the development of specifically targeted ADCs for hard-to-treat cancers.

Development 130

Development 130

Advertisement

The sourcing of commercial drugs for use in clinical trials either as a comparator, rescue or co-medication can be a complex process. Sponsors can face a number of challenges when trying to obtain these critical supplies for their studies, including addressing product lead times, availability, expiry limitations, safety and cost, among others. Choosing the right partner with global sourcing, regulatory, quality and clinical packaging expertise can provide the necessary guidance to help sponsors

Clinical Trials

Fierce Pharma

SEPTEMBER 22, 2023

Fast on the heels of winning a European approval to treat chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim's versatile SGLT2 inhibitor Jardiance is expanding its reach in the U.S., | After AstraZeneca's Farxiga won a class-first chronic kidney disease approval back in 2021, Eli Lilly and Boehringer are entering the fray with their SGLT2 drug Jardiance.

Drugs 121

Drugs 121

Pharmaceutical Technology

SEPTEMBER 22, 2023

The WHO and the World Bank have published the 2023 UHC Global Monitoring Report, detailing global health spending and service coverage rate.

Marketing 130

Marketing 130

Fierce Pharma

SEPTEMBER 22, 2023

It’s not a proper market showdown without all the players. | It’s not a proper market showdown without all the players. In the perioperative treatment of early-stage non-small cell lung cancer with a PD-1/L1 inhibitor, Bristol Myers Squibb is touting a new trial win. The results follow positive readouts from AstraZeneca and Merck.

Drugs 118

Drugs Trials Marketing 118

Pharmaceutical Technology

SEPTEMBER 22, 2023

The UK-based surgical robotics company has now raised over $1bn in funding, cementing its unicorn status as it passes 15,000 surgeries.

Development 130

Development 130

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Fierce Pharma

SEPTEMBER 22, 2023

As Seagen prepares for its takeover by Pfizer, the company’s Astellas-partnered cancer drug Padcev has chalked up a key trial win—in combination with Merck's Keytruda—in previously untreated metast | In a critical win, the Padcev-Keyturda combo significantly reduced the risk of death in first-line bladder cancer patients who are eligible for platinum-based chemotherapy at an interim analysis of the closely watched EV-302 trial.

Trials 118

Trials Drugs 118

Pharmaceutical Technology

SEPTEMBER 22, 2023

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in Glenmark Life Sciences for $679.85m.

Life Science 130

Life Science 130

Pharmaceutical Commerce

SEPTEMBER 22, 2023

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Drugs 105

Drugs Pharmacy Branding Production 105

Pharmaceutical Technology

SEPTEMBER 22, 2023

Novo Holdings has acquired Paratek Pharmaceuticals for nearly $462m to bolster its antimicrobial resistance (AMR) expertise.

130

130

Advertisement

As demand for advanced therapies increases, so does the need for more specialized supply chain support, as these products have strict transportation and handling requirements. Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.

Gene Therapy

Pharma Times

SEPTEMBER 22, 2023

The collaboration will utilise Evaxion’s EDEN-discovered antigen targets - News - PharmaTimes

Vaccination 130

Vaccination Vaccine Development 130

Fierce Pharma

SEPTEMBER 22, 2023

A story this week about an FDA Form 483 filing for an Ajinomoto site in San Diego was reported in error. While the site did receive FDA observations in early 2023, the inspection has since closed. | A story published Sept. 19 about an Ajinomoto site in San Diego has been retracted.

98

98

Pharma Times

SEPTEMBER 22, 2023

IDAP aims to address unmet clinical needs for patients and healthcare professionals - News - PharmaTimes

115

115

Drug Channels

SEPTEMBER 22, 2023

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. Kristina shares the story of a patient who cut pills in half to extend her prescriptions. Unfortunately, this patient didn’t know about manufacturer affordability programs. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, whether at the prescriber’s office, the pharmacy, or at home.

Pharmacy 90

Pharmacy Drugs Manufacturing Branding 90

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

pharmaphorum

SEPTEMBER 22, 2023

Machine learning puts virtual drug screening into high gear Phil.

Drugs 124

Drugs 124

Drug Channels

SEPTEMBER 22, 2023

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. Kristina shares the story of a patient who cut pills in half to extend her prescriptions. Unfortunately, this patient didn’t know about manufacturer affordability programs. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, whether at the prescriber’s office, the pharmacy, or at home.

Pharmacy 73

Pharmacy Drugs Manufacturing Branding 73

pharmaphorum

SEPTEMBER 22, 2023

Seagen hails ‘practice-changing’ trial in bladder cancer Phil.

Trials 111

Trials 111

XTalks

SEPTEMBER 22, 2023

Recent initial public offerings (IPOs) from food companies such as Cava Group and BranchOut Food might give the impression of a reawakening IPO market after a seemingly quiet year. However, EY’s latest Global IPO Trends report for the second quarter of 2023 suggests otherwise. While a few IPOs have captured media attention, the broader US IPO scene remains muted.

Branding 64

Branding Licensing Licensing Marketing 64

Advertisement

There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.

Trials

pharmaphorum

SEPTEMBER 22, 2023

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer Phil.

Drugs 105

Drugs 105

Drug Patent Watch

SEPTEMBER 22, 2023

Annual Drug Patent Expirations for ACTHAR+GEL Acthar Gel is a drug marketed by Mallinckrodt Ard and is included in one NDA. It is available from one supplier. The generic ingredient… The post New patent for Mallinckrodt Ard drug ACTHAR GEL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

pharmaphorum

SEPTEMBER 22, 2023

Travere weaker after Filspari fails confirmatory trial Phil.

Trials 105

Trials 105

Drug Patent Watch

SEPTEMBER 22, 2023

Annual Drug Patent Expirations for BYLVAY Bylvay is a drug marketed by Albireo and is included in one NDA. It is available from one supplier. There are eight patents protecting… The post New patent for Albireo drug BYLVAY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials